...
首页> 外文期刊>The Journal of Steroid Biochemistry and Molecular Biology >A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors
【24h】

A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors

机译:用于对类固化性途径动力学的体外评估的稳态系统:CYP11B1,CYP11B2和CYP17抑制剂的应用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Disorders featuring dysregulated adrenal steroidogenesis, such as primary aldosteronism, can benefit from targeted therapies. The aldosterone and cortisol producing enzymes, aldosterone synthase (CYP11B2) and 11-betahydroxylase (CYP11B1), share 93% homology requiring selective drugs for pharmacological treatment. Herein, we introduce an effective in vitro assay for evaluation of steroidogenic enzyme kinetics based on intracellular flux calculations. H295RA cells were cultured in chambers under constant medium flow. Four hourly samples were collected (control samples), followed by collections over an additional four hours after treatment with fadrozole (10 nM), metyrapone (10 pM), SI_191 (5 nM), a novel CYP11B2 inhibitor or SI 254 (100 nM), a newly synthesized 17-alpha-hydroxylase/17,20-lyase inhibitor. Mass spectrometric measurements of multiple steroids combined with linear system computational modeling facilitated calculation of intracellular fluxes and changes in rate constants at different steroidogenic pathway steps, enabling selectivity of drugs for those steps to be evaluated. While treatment with fadrozole, metyrapone and SI 191 all reduced fluxes of aldosterone, corticosterone and cortisol production, treatment with SI_254 led to increased flux through the mineralocorticoid pathway and reduced production of steroids downstream of 17-alpha-hydroxylase/17,20-lyase. Drug-induced decreases in rate constants revealed higher selectivity of SI_191 compared to other drugs for CYP11B2 over CYP11B1, this reflecting additional inhibitory actions of SI191 on catalytic steps of CYP11B2 downstream from the initial 11-beta-hydroxlase step. By culturing cells under perfusion the described system provides a realistic model for simple and rapid calculations of intracellular fluxes and changes in rate constants, thereby offering a robust procedure for investigating drug or other effects at specific steps of steroidogenesis.
机译:疾病具有疑难解失常的肾上腺甾体系,例如原发性醛固酮,可以受益于有针对性的疗法。醛固酮和皮质醇生产酶,醛固酮合成酶(CYP11B2)和11-甲基甲基酶(CYP11B1),共享93%的同源性需要选择性药物治疗药物治疗。在此,我们在基于细胞内通量计算的基础上介绍了用于评估类化酶动力学的有效体外测定。在恒定介质流动下在腔室中培养H295RA细胞。收集四个小时样品(对照样品),然后在用三唑(10nm)处理后另外四小时内收集,甲嘧啶(10mm),Si_191(5nm),一种新型Cyp11b2抑制剂或Si 254(100nm) ,新合成的17-α-羟化酶/ 17,20-裂解酶抑制剂。多种类固醇的质谱测量结合线性系统计算建模的促进细胞内通量计算和不同类体途径步骤的速率常数变化,使得药物的选择性用于评估这些步骤。虽然用三唑唑,梅罗布酮和Si 191治疗所有醛固酮,皮质酮和皮质醇生产的助熔剂,但用Si_254治疗导致通过矿物皮质途径的助焊剂增加,并降低了17-α-羟化酶/ 17,20-裂纹酶下游的类固醇。与CYP11B2上的CYP11B2的其他药物相比,速率常数的药物诱导的速率降低显示了Si_191的选择性,这反映了Si191对初始11-β-羟基溶酶步骤的下游CYP11B2的催化步骤的附加抑制作用。通过灌注下的细胞,所描述的系统提供了一种易于计算细胞内通量和速率常数变化的简单和快速计算的现实模型,从而为在类定量发生的特定步骤中调查药物或其他效果提供稳健的程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号